Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies.

Eur J Endocrinol

Department of EndocrinologyUniversity Medical Centre Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The NetherlandsDepartment of GeneticsErasmus Medical Centre, Rotterdam, The NetherlandsDepartment of Surgical OncologyUniversity Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Published: June 2015

The treatment for metastasised medullary thyroid cancer is still a topic of discussion. One of the main challenges remains to find effective adjuvant and palliative options for patients with metastatic disease. The diagnostic and treatment strategies for this tumour are discussed and possible new developments commented. Approaches that target rearranged during transfection (RET) are preferable to those that target RET downstream proteins as, theoretically, blocking RET downstream targets will block only one of the many pathways activated by RET. Combining several agents would seem to be more promising, in particular agents that target RET with those that independently target RET signalling pathways or the more general mechanism of tumour progression.

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-14-0726DOI Listing

Publication Analysis

Top Keywords

target ret
12
medullary thyroid
8
ret downstream
8
ret
6
endocrine tumours
4
tumours progressive
4
progressive metastatic
4
metastatic medullary
4
thyroid carcinoma
4
carcinoma first-
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!